NCT05626530View on ClinicalTrials.gov

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

PHASE4RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2025

Conditions
Cytomegalovirus InfectionsInfection in Solid Organ Transplant RecipientsNeutropeniaAntiviral Toxicity
Interventions
DRUG

Letermovir

Open label 480 mg given daily for 60 days

Trial Locations (1)

02111

RECRUITING

Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston

All Listed Sponsors
lead

Tufts Medical Center

OTHER